Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing…
| Price | $276.99 |
|---|---|
| Market cap | $13.34B |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Exchange | NYSE |
| 52-week range | 144.26-303.31 |
| Beta | 1.41 |
Explore CRL's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.